Study tests novel treatment developed at Beth Israel Deaconess Medical Center
BOSTON -- A new treatment can help nonverbal children with autism to develop speech, according to a proof-of-concept study led by researchers at Beth Israel Deaconess Medical Center (BIDMC).
Known as Auditory-Motor Mapping Training (AMMT), the novel treatment builds on the observations that children with autism – who typically struggle with communication, as well as social interactions – often respond positively to music. The findings are reported in the September 29, 2011 issue of the journal PLoS One.
"Communication deficits are one of the core symptoms of autism," explains first author Catherine Wan, PhD, a researcher in the Music and Neuroimaging Laboratory of BIDMC's Department of Neurology and an Instructor of Neurology at Harvard Medical School (HMS). "It has been estimated that up to 25 percent of all children with autism are nonverbal, but surprisingly, not much is out there treatment-wise that directly helps these children to speak." Autism affects an estimated one in 110 children and one in 70 boys.
The AMMT treatment uses a combination of singing (intonation) and motor activities to strengthen a network of brain regions that is thought to be abnormal in children with autism. "We developed AMMT, in part, because another intonation-based therapy, known as Melodic Intonation Therapy, had been successful in helping stroke patients with aphasia recover their ability to speak," adds senior author Gottfried Schlaug, MD, PhD, Director of the Music and Neuroimaging Laboratory at BIDMC and Associate Professor of Neurology at HMS.
After eight weeks of AMMT treatment (five days per week), the six children in the proof-of-concept study -- who ranged in age from six to nine and were previously completely nonverbal -- were able to approximate whole words and phrases. The children could also generalize their speech production to words that were not practiced during the therapy. "Noticeable improvements in speech were seen as early as two weeks into the treatment," explains Wan. "More importantly, the improvements lasted as long as two months after the treatment sessions ended.
"In the future, we plan to compare the effectiveness of AMMT with a control intervention," she adds. "For these nonverbal children to say their first words is especially gratifying for parents, and represents a critical step forward in their language development."
This study was supported by The Nancy Lurie Marks Family Foundation and the Deborah Munroe Noonan Memorial Research Fund.
In addition to Wan and Schlaug, study coauthors include BIDMC investigators Loes Bazen, Rebecca Baars, Amanda Libenson, Jennifer Zuk and Andrea Norton, all of the Music and Neuroimaging Laboratory; and Lauryn Zipse of the MGH Institute of Health Professions.
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and ranks third in National Institutes of Health funding among independent hospitals nationwide. BIDMC is a clinical partner of the Joslin Diabetes Center and a research partner of the Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org.